Segment Data

9 Months Ended

Jun. 30, 2012

Segment Data [Abstract]

Segment Data

Note 6 – Segment Data

The Company’s organizational structure is based upon its three principal business segments: BD Medical (“Medical”), BD Diagnostics (“Diagnostics”) and BD Biosciences (“Biosciences”). These segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services. The Company evaluates performance of its business segments and allocates resources to them primarily based upon operating income. Segment operating income represents revenues reduced by product costs and operating expenses. From time to time, the Company hedges against certain forecasted sales of U.S.-produced products sold outside the United States. Gains and losses associated with these foreign currency translation hedges are reported in segment revenues based upon their proportionate share of these international sales of U.S.-produced products. Financial information for the Company’s segments was as follows:

	Three Months Ended June 30,						Nine Months Ended June 30,
	2012			2011			2012			2011
Revenues (A)
Medical	$	1,070,076		$	1,044,836		$	3,041,660		$	2,952,713
Diagnostics		642,250			631,359			1,893,012			1,838,429
Biosciences		268,204			275,694			806,539			804,714
	$	1,980,530		$	1,951,889		$	5,741,211		$	5,595,856
Segment Operating Income
Medical	$	323,868		$	324,170		$	862,856		$	887,080
Diagnostics		173,535			164,293			496,950			481,322
Biosciences		67,157			64,472			199,582			202,403
Total Segment Operating Income		564,560			552,935			1,559,388			1,570,805
Unallocated Items (B)		(146,019	)		(117,765	)		(448,879	)		(346,792	)
Income from Continuing Operations Before Income Taxes	$	418,541		$	435,170		$	1,110,509		$	1,224,013

(A) Intersegment revenues are not material.

(B) Includes primarily interest, net; foreign exchange; corporate expenses; and share-based compensation expense.

	Three Months Ended June 30,				Nine Months Ended June 30,
	2012		2011		2012		2011
Revenues by Organizational Units
BD Medical
Medical Surgical Systems	$	531,771	$	529,018	$	1,573,020	$	1,546,334
Diabetes Care		232,675		220,184		677,839		641,826
Pharmaceutical Systems		305,630		295,634		790,801		764,553
	$	1,070,076	$	1,044,836	$	3,041,660	$	2,952,713
BD Diagnostics
Preanalytical Systems	$	333,454	$	330,326	$	973,389	$	949,194
Diagnostic Systems		308,796		301,033		919,623		889,235
	$	642,250	$	631,359	$	1,893,012	$	1,838,429
BD Biosciences
Cell Analysis (1)	$	268,204	$	275,694	$	806,539	$	804,714
	$	268,204	$	275,694	$	806,539	$	804,714
	$	1,980,530	$	1,951,889	$	5,741,211	$	5,595,856

(1) Cell Analysis consists of the Cell Analysis unit and the Advanced Bioprocessing platform.

Revenues by geographic areas were as follows:

	Three Months Ended June 30,				Nine Months Ended June 30,
	2012		2011		2012		2011
Total Revenues
United States	$	836,535	$	827,445	$	2,463,858	$	2,433,109
International		1,143,995		1,124,444		3,277,353		3,162,747
	$	1,980,530	$	1,951,889	$	5,741,211	$	5,595,856